Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$67.42 +4.6%	$51.69	$20.14 ▼ $67.51	$8.04B	1.43	2.82 million shs	2.86 million shs
HIMS Hims & Hers Health	$42.36 -4.0%	$49.98	$13.47 ▼ $72.98	$9.97B	2.08	29.95 million shs	16.08 million shs
OPCH Option Care Health	$28.68 -0.2%	$29.60	$21.39 ▼ $35.53	$4.67B	0.79	1.81 million shs	1.55 million shs
PGNY Progyny	$23.67 +1.8%	$22.73	$13.39 ▼ $26.76	$2.00B	1.32	1.15 million shs	1.08 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	+1.53%	+5.21%	+48.82%	+58.21%	+146.07%
HIMS Hims & Hers Health	+0.23%	+0.83%	-26.74%	-22.16%	+201.70%
OPCH Option Care Health	+0.56%	+3.27%	-4.58%	-12.43%	-8.53%
PGNY Progyny	+1.00%	+0.52%	+1.84%	+6.36%	+6.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GH Guardant Health	3.2401 of 5 stars	1.5	2.0	4.4	3.5	2.5	0.6
HIMS Hims & Hers Health	2.8874 of 5 stars	2.0	3.0	0.0	2.5	3.3	2.5
OPCH Option Care Health	4.5338 of 5 stars	2.4	3.0	4.3	4.3	3.3	1.9
PGNY Progyny	2.9866 of 5 stars	2.4	2.0	0.0	3.5	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GH Guardant Health	3.06	Buy	$57.50	-14.71% Downside
HIMS Hims & Hers Health	1.92	Reduce	$38.92	-8.13% Downside
OPCH Option Care Health	2.89	Moderate Buy	$35.75	24.65% Upside
PGNY Progyny	2.73	Moderate Buy	$25.30	6.89% Upside

Current Analyst Ratings Breakdown

Latest PGNY, HIMS, OPCH, and GH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	PGNY Progyny	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $25.00
8/20/2025	PGNY Progyny	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$21.00 ➝ $23.00
8/19/2025	HIMS Hims & Hers Health	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$48.00 ➝ $37.00
8/8/2025	PGNY Progyny	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$28.00
8/8/2025	PGNY Progyny	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$26.00 ➝ $28.00
8/5/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/31/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$36.00 ➝ $38.00
7/31/2025	OPCH Option Care Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/31/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$57.00 ➝ $60.00
7/31/2025	GH Guardant Health	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$59.00 ➝ $61.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GH Guardant Health	$739.02M	11.38	N/A	N/A	($2.45) per share	-27.52
HIMS Hims & Hers Health	$1.48B	6.48	$0.34 per share	125.28	$2.49 per share	17.01
OPCH Option Care Health	$5.00B	0.93	$1.64 per share	17.48	$8.38 per share	3.42
PGNY Progyny	$1.17B	1.74	$0.35 per share	67.37	$5.99 per share	3.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GH Guardant Health	-$436.37M	-$3.35	N/A	N/A	N/A	-49.93%	N/A	-28.95%	11/5/2025 (Estimated)
HIMS Hims & Hers Health	$126.04M	$0.80	52.95	81.46	2.98	9.63%	26.26%	13.06%	11/3/2025 (Estimated)
OPCH Option Care Health	$211.82M	$1.25	22.94	22.76	1.75	3.93%	17.53%	7.17%	10/29/2025 (Estimated)
PGNY Progyny	$54.34M	$0.59	40.12	36.42	1.90	4.28%	10.69%	7.12%	11/11/2025 (Estimated)

Latest PGNY, HIMS, OPCH, and GH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PGNY Progyny	$0.42	$0.19	-$0.23	$0.19	$315.70 million	$332.87 million
8/4/2025	Q2 2025	HIMS Hims & Hers Health	$0.18	$0.17	-$0.01	$0.17	$550.06 million	$544.83 million
7/30/2025	Q2 2025	GH Guardant Health	-$0.52	-$0.44	+$0.08	-$0.80	$211.19 million	$232.09 million
7/30/2025	Q2 2025	OPCH Option Care Health	$0.40	$0.41	+$0.01	$0.31	$1.35 billion	$1.42 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
OPCH Option Care Health	N/A	N/A	N/A	N/A	N/A
PGNY Progyny	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GH Guardant Health	N/A	3.71	3.35
HIMS Hims & Hers Health	1.72	4.98	4.46
OPCH Option Care Health	0.81	1.52	1.00
PGNY Progyny	N/A	2.70	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GH Guardant Health	92.60%
HIMS Hims & Hers Health	63.52%
OPCH Option Care Health	98.05%
PGNY Progyny	94.93%

Insider Ownership

Company	Insider Ownership
GH Guardant Health	6.10%
HIMS Hims & Hers Health	13.71%
OPCH Option Care Health	0.64%
PGNY Progyny	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GH Guardant Health	2,021	124.71 million	117.10 million	Not Optionable
HIMS Hims & Hers Health	1,637	226.02 million	195.03 million	Optionable
OPCH Option Care Health	8,088	162.29 million	161.26 million	Optionable
PGNY Progyny	310	85.98 million	77.90 million	Optionable

PGNY, HIMS, OPCH, and GH Headlines

Recent News About These Companies

Wellington Management Group LLP Boosts Stock Position in Progyny, Inc. $PGNY

August 29 at 3:57 AM | marketbeat.com

Russell Investments Group Ltd. Boosts Stake in Progyny, Inc. $PGNY

August 28 at 3:37 AM | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for Progyny (NASDAQ:PGNY) Stock Price

August 28 at 2:13 AM | americanbankingnews.com

Progyny (PGNY) Stock Trades Up, Here Is Why

August 27 at 5:34 PM | msn.com

Progyny, Inc. $PGNY Position Lessened by Thematics Asset Management

August 27 at 7:42 AM | marketbeat.com

Capital Fund Management S.A. Has $2.41 Million Stock Position in Progyny, Inc. $PGNY

August 27 at 4:49 AM | marketbeat.com

Progyny price target raised to $25 from $23 at JPMorgan

August 26 at 6:52 PM | msn.com

A Glimpse Into The Expert Outlook On Progyny Through 5 Analysts

August 26 at 6:52 PM | benzinga.com

Charles Schwab Investment Management Inc. Has $15.40 Million Holdings in Progyny, Inc. $PGNY

August 25, 2025 | marketbeat.com

610,804 Shares in Progyny, Inc. $PGNY Purchased by Nuveen LLC

August 24, 2025 | marketbeat.com

Progyny (NASDAQ:PGNY) Price Target Raised to $23.00

August 22, 2025 | marketbeat.com

Progyny, Inc. $PGNY Shares Acquired by Quantbot Technologies LP

August 22, 2025 | marketbeat.com

Algert Global LLC Buys 22,260 Shares of Progyny, Inc. $PGNY

August 22, 2025 | marketbeat.com

Vanguard Group Inc. Trims Holdings in Progyny, Inc. $PGNY

August 22, 2025 | marketbeat.com

1 Russell 2000 Stock with Impressive Fundamentals and 2 We Ignore

August 21, 2025 | finance.yahoo.com

Progyny (NASDAQ:PGNY) Price Target Raised to $23.00 at Canaccord Genuity Group

August 21, 2025 | americanbankingnews.com

Progyny price target raised to $23 from $21 at Canaccord

August 20, 2025 | msn.com

Versor Investments LP Invests $1.05 Million in Progyny, Inc. $PGNY

August 20, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Progyny, Inc. $PGNY

August 20, 2025 | marketbeat.com

Progyny, Inc. (NASDAQ:PGNY) Receives $24.90 Average PT from Brokerages

August 20, 2025 | americanbankingnews.com

Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Public Sector Pension Investment Board

August 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PGNY, HIMS, OPCH, and GH Company Descriptions

Guardant Health NASDAQ:GH

$67.42 +2.95 (+4.58%)

Closing price 04:00 PM Eastern

Extended Trading

$67.32 -0.10 (-0.15%)

As of 07:59 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health NYSE:HIMS

$42.36 -1.76 (-3.99%)

Closing price 03:59 PM Eastern

Extended Trading

$42.58 +0.23 (+0.53%)

As of 08:00 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Option Care Health NASDAQ:OPCH

$28.68 -0.07 (-0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$28.68 +0.00 (+0.00%)

As of 07:54 PM Eastern

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

Progyny NASDAQ:PGNY

$23.67 +0.42 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$23.50 -0.17 (-0.71%)

As of 04:47 PM Eastern

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time